5-aminolevulinic Acid In Advanced Malignancies
NCT04443686
Recruiting
This is a phase 1, open label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study to determine the maximum tolerated doses (MTD) or recommended phase 2 doses (RP2D) of both ALA and RT. Once the MTDs are identified, the cohort providing the highest dose intensity at or below the MTD (if supported by emerging PK and biomarker data) will be selected for an expansion phase for the purpose of refining the safety assessment and assessing preliminary efficacy. The initial dose escalati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715
Recruiting
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2023
Locations: National Human Genome Research Institute, Bethesda, Maryland +99 locations
Conditions: Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome
Register for Updates
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
NCT05694195
Recruiting
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
Gender:
All
Ages:
Between 18 years and 82 years
Trial Updated:
02/17/2023
Locations: Orlando Clinical Research Center, Orlando, Florida +1 locations
Conditions: Renal Insufficiency, Kidney Diseases
Register for Updates
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Register for Updates
Artificial Intelligence (AI) Cytopathology Trial
NCT05018663
Recruiting
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/15/2023
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Pancreatic Solid Lesions
Register for Updates
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
NCT03231644
Recruiting
The FD/MAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD/MAS by completing questionnaires about their lives with FD or MAS. Have you enrolled in the FD/MAS Patient Registry yet? Are you up-to-date on your surveys? Take a trip to www.fdmasregistry.org today to learn more about the project, enroll, complete your surveys, or make sure you aren't due to provide more info! The FD/MAS Patient Regis... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/13/2023
Locations: Tovah Burstein, Bethesda, Maryland
Conditions: Fibrous Dysplasia, McCune Albright Syndrome, Mazabraud Syndrome
Register for Updates
HyperArc Registry Study
NCT05270707
Recruiting
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2023
Locations: University of Alabama, Birmingham, Alabama +4 locations
Conditions: Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
Register for Updates
LIFT Intervention in Liver Transplant Candidates
NCT04836923
Recruiting
Frailty is a significant problem in patients undergoing liver transplant and is associated with poor outcomes and survival. Hence, optimizing physical fitness and counteracting frailty is important. However, many interventions are very resource intensive and therefore not feasible. In this study, the investigators aim to test the effectiveness of a newly designed intervention to improve frailty in liver transplant candidates. The "LIver FrailTy" intervention (LIFT) will consist of an evaluation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2023
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Frailty, Cirrhosis, Liver Transplant
Register for Updates
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
NCT04284280
Recruiting
The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.
Gender:
ALL
Ages:
Between 0 days and 6 days
Trial Updated:
02/09/2023
Locations: Crouse Hospital, Syracuse, New York
Conditions: Poor Growth in Extremely Preterm Infants, Necrotizing Enterocolitis
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
NCT05736029
Recruiting
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Non Small Cell Lung Cancer, Healthy
Register for Updates
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: City of Hope, Duarte, California +9 locations
Conditions: Cancer
Register for Updates
Preventing Tipping Points in High Comorbidity Patients: A Lifeline From Health Coaches
NCT04176510
Recruiting
This pragmatic cluster randomized clinical trial (cRCT) aims to evaluate the comparative effectiveness (CER) of two approaches to preventing destabilization ("tipping points") that lead to unplanned hospitalization and increased disability. The cRCT compares the outcomes of patients randomized in clusters by site within four Federally Qualified Health Center (FQHC) networks in New York City (NYC) and Chicago to either: 1) the Patient Centered Medical Home (PCMH); or 2) the Patient Centered Home... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Friend Health, Inc., Chicago, Illinois +3 locations
Conditions: Comorbidity, Self-Management
Register for Updates